Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Genetic Technologies Limited

Investor presentation - Genetic Technologies Limited

ASX:GTG

Genetic Technologies Limited

Health

Genetic Technologies Limited (GTG) is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product is BREVAGenplus.

Market Cap

$99.14m

Price at Close

$0.012

4w avg. Volume

17.18m

4w avg. Turnover

$186.07k

Announcements
announcementt+2 movementdate
  • Genetic Technologies US$6.56 Million Capital Raising

    Issued Capital · Market sensitive

  • -

    21 Jan 2021

-

21 Jan 2021
  • Investor Presentation

    Periodic Reports

  • +12.50%

    12 Jan 2021

+12.50%

12 Jan 2021
  • Genetic Technologies appoints Simon Morriss as CEO

    Company Administration · Market sensitive

  • 0.00%

    03 Jan 2021

0.00%

03 Jan 2021
  • Change of Directors' Interest Notices

    Shareholder Details

  • +14.29%

    24 Dec 2020

+14.29%

24 Dec 2020
  • Appendix 3G

    Issued Capital

  • 0.00%

    21 Dec 2020

0.00%

21 Dec 2020
  • Results of Meeting

    Notice Of Meeting

  • -20.00%

    10 Dec 2020

-20.00%

10 Dec 2020
  • AGM Presentation

    Periodic Reports

  • +14.29%

    09 Dec 2020

+14.29%

09 Dec 2020
  • Chairman's AGM Address

    Chairman's Address

  • +14.29%

    09 Dec 2020

+14.29%

09 Dec 2020
  • Updated Announcement

    Progress Report

  • 0.00%

    01 Dec 2020

0.00%

01 Dec 2020
  • GTG Secures US and ANZ Distribution Rights for PREDICTIX

    Progress Report · Market sensitive

  • 0.00%

    30 Nov 2020

0.00%

30 Nov 2020
Market Data

Current Price

$0.012

52WK HIGH

$0.014

52WK LOW

$0.003

1YR RETURN

+9.09%

1YR RETURN VS. SECTOR

-29.60%

90 DAY RETURN

+50.00%

ASX RANK

893

/2,048

SECTOR RANK

77

/168

SHARES OUTSTANDING

8.26b
ASX:GTG

Genetic Technologies Limited

Health

Genetic Technologies Limited (GTG) is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product is BREVAGenplus.

Market Cap

$99.14m

Price at Close

$0.012

4w avg. Volume

17.18m

4w avg. Turnover

$186.07k

ASX:GTG is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.